BioAdvance

Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.

Innervace is a regenerative therapy company based in Philadelphia, Pennsylvania, focused on developing implantable tissue-engineered brain pathways to address neurodegenerative disorders. The company specializes in creating anatomically inspired living scaffolds designed for brain pathway reconstruction. Its lead clinical product is a tissue-engineered nigrostriatal pathway, which aims to replicate the lost pathway in patients with Parkinson's disease. By concentrating on the reconstruction of brain pathways rather than merely alleviating symptoms temporarily, Innervace offers innovative solutions that aim to improve the quality of life for individuals affected by these conditions. Established in 2018, the company is dedicated to advancing its products from development to commercialization.

Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.

Renovacor, Inc. is a preclinical-stage biopharmaceutical company based in Philadelphia, Pennsylvania, dedicated to developing gene therapies for cardiovascular diseases. Founded in 2013, the company focuses on innovative treatments for dilated cardiomyopathy (DCM), particularly cases caused by mutations in the BAG3 gene. This condition affects over 3 million individuals in the United States, with around 35,000 patients estimated to have BAG3 mutations, classifying it as an orphan disease. Patients with BAG3-associated DCM, often younger and experiencing faster disease progression, currently have limited treatment options, primarily consisting of standard heart failure care. Renovacor's lead program involves a recombinant adeno-associated virus (AAV)-based gene therapy aimed at replacing the defective BAG3 gene, which holds the potential to prevent disease progression and improve outcomes for this vulnerable patient population.

Opsidio is a biotechnology company based in Bryn Mawr, Pennsylvania, founded in 2012. The company specializes in developing monoclonal antibodies aimed at treating fibrotic and remodeling diseases, as well as allergic conditions. Opsidio's innovative antibodies specifically target a unique form of the Stem Cell Factor, which plays a crucial role in the cascade of profibrotic cytokines. This targeted approach enables healthcare providers to address various serious conditions, including idiopathic pulmonary fibrosis, chronic kidney disease, systemic sclerosis, and severe asthma, ultimately improving treatment options for affected patients.

Oncora Medical, Inc. is a digital health company focused on enhancing radiation oncology through an innovative analytics platform. Founded in 2014 and based in Philadelphia, Pennsylvania, the company provides tools that facilitate the integration of clinical data from electronic medical records, treatment planning software, and oncology information systems. This allows radiation oncologists to make personalized treatment recommendations based on historical data and predictive analytics. The platform also employs machine learning algorithms to analyze patient outcomes, enabling oncologists to improve cancer care and optimize treatment strategies. By leveraging real-world data, Oncora Medical aims to support better healthcare decisions and ultimately enhance patient outcomes in radiation oncology.

CytoVas LLC is a life science company based in Philadelphia, Pennsylvania, that specializes in developing an innovative informatics platform, CLOUD CYTOMICS. This platform is designed to analyze flow cytometry data, providing clinicians and drug developers with actionable insights on novel cellular markers related to disease progression and individual treatment responses. By automating data collection and interpretation, CLOUD CYTOMICS enables rapid identification of cellular biomarkers, facilitating critical decision-making in the development of targeted therapies. The technology is applicable across various therapeutic areas, including cardiovascular disease, type 2 diabetes, Alzheimer’s, and more. Founded by experts in computational biology and flow cytometry from the University of Pennsylvania, CytoVas is supported by significant investments from organizations such as the American Heart Association and the National Institutes of Health, as well as a partnership with Becton Dickinson Biosciences. The company continues to explore the potential of its platform in diverse medical research fields.

Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.

Venatorx Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections and challenging viral infections. Founded in 2010 and based in Malvern, Pennsylvania, the company specializes in developing antibacterial drugs to combat resistant infections commonly encountered in hospital and community settings, such as those caused by MRSA, Pseudomonas spp., and Salmonella spp. Venatorx employs innovative chemical approaches to create treatments that exhibit selective and potent activity against various resistant bacterial strains, thereby providing healthcare professionals with broader treatment options to address significant unmet medical needs.

Keriton LLC is a provider of a pumped breast milk management system specifically designed for neonatal intensive care units (NICUs). Based in Philadelphia, Pennsylvania, the company offers a comprehensive platform that enhances patient safety and streamlines nursing workflows. This system enables healthcare professionals to track milk-bottle inventory, manage feeding orders, and handle first-in-first-out (FIFO) bottle flow, including notifications for expiry dates and misfeed alerts. The platform also facilitates real-time insights into lactating mothers' milk production patterns and includes a media-sharing feature for nurses to communicate with mothers by sharing photos and videos of their babies. With a track record of managing over 1.5 million feeds and preventing nearly 30,000 errors, Keriton's solution aims to improve health outcomes and reduce the cognitive burden on hospital staff. Since its incorporation in 2016, Keriton has been deployed in numerous larger enterprise health systems, demonstrating its effectiveness in enhancing the care provided to infants in NICUs.

Mebias Discovery, LLC is a pharmaceutical company focused on discovering and developing pathway-selective drugs that target G-protein coupled receptors (GPCRs). Founded in 2015 and based in Philadelphia, Pennsylvania, Mebias aims to create next-generation GPCR drugs that minimize on-target side effects traditionally associated with these therapies. The company utilizes a validated drug discovery platform to identify molecules that can selectively bind to GPCRs, which may lead to improved treatment options for a range of conditions, including neurodegenerative disorders, mood disorders, non-opioid pain management, cardiovascular diseases, and immuno-oncology. By employing this innovative approach, Mebias Discovery seeks to reduce the risks commonly associated with conventional drug development methods, thus providing new therapeutic avenues for various health issues.

Immunome Inc., founded in 2006 and headquartered in Exton, Pennsylvania, is a biotechnology company focused on discovering, developing, and commercializing highly targeted and native human cancer antibodies against universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that target them. Additionally, Immunome employs ScreenMab multiplex functional screening technology to pinpoint monoclonal antibodies with high specificity for tumor neoantigens.

Mebias Discovery, LLC is a pharmaceutical company focused on discovering and developing pathway-selective drugs that target G-protein coupled receptors (GPCRs). Founded in 2015 and based in Philadelphia, Pennsylvania, Mebias aims to create next-generation GPCR drugs that minimize on-target side effects traditionally associated with these therapies. The company utilizes a validated drug discovery platform to identify molecules that can selectively bind to GPCRs, which may lead to improved treatment options for a range of conditions, including neurodegenerative disorders, mood disorders, non-opioid pain management, cardiovascular diseases, and immuno-oncology. By employing this innovative approach, Mebias Discovery seeks to reduce the risks commonly associated with conventional drug development methods, thus providing new therapeutic avenues for various health issues.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing small molecule drugs and therapeutics aimed at treating various chronic diseases. Established in 2004, the company specializes in creating peripherally selective agents for conditions such as diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), obesity, autoimmune and inflammatory disorders, and malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these therapeutic areas.

Penn State Health is a multi-hospital health system that serves patients and communities across Central Pennsylvania. It includes the Milton S. Hershey Medical Center, a 551-bed Level I regional trauma center recognized for its expertise in complex adult and pediatric cases. As the region's only academic medical center, it is closely affiliated with the Penn State College of Medicine and houses the Children's Hospital at Penn State Health. The medical center has achieved ANCC Magnet Recognition, reflecting its dedication to fostering a supportive professional environment for staff and delivering high-quality patient care.

Noble.MD is a healthcare technology company based in Bryn Mawr, Pennsylvania, founded in 2012. The company develops Theo, a digital healthcare advisory platform designed to assist patients in identifying health and behavioral risks. The platform actively engages patients by providing programs and interventions to help them manage these risks. By capturing essential patient data at the time of care, Noble.MD facilitates value-based reimbursement and aligns the interests of providers and payers, enhancing the processes of risk identification, coding, and management.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing small molecule drugs and therapeutics aimed at treating various chronic diseases. Established in 2004, the company specializes in creating peripherally selective agents for conditions such as diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), obesity, autoimmune and inflammatory disorders, and malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these therapeutic areas.

Oncora Medical, Inc. is a digital health company focused on enhancing radiation oncology through an innovative analytics platform. Founded in 2014 and based in Philadelphia, Pennsylvania, the company provides tools that facilitate the integration of clinical data from electronic medical records, treatment planning software, and oncology information systems. This allows radiation oncologists to make personalized treatment recommendations based on historical data and predictive analytics. The platform also employs machine learning algorithms to analyze patient outcomes, enabling oncologists to improve cancer care and optimize treatment strategies. By leveraging real-world data, Oncora Medical aims to support better healthcare decisions and ultimately enhance patient outcomes in radiation oncology.

Mebias Discovery, LLC is a pharmaceutical company focused on discovering and developing pathway-selective drugs that target G-protein coupled receptors (GPCRs). Founded in 2015 and based in Philadelphia, Pennsylvania, Mebias aims to create next-generation GPCR drugs that minimize on-target side effects traditionally associated with these therapies. The company utilizes a validated drug discovery platform to identify molecules that can selectively bind to GPCRs, which may lead to improved treatment options for a range of conditions, including neurodegenerative disorders, mood disorders, non-opioid pain management, cardiovascular diseases, and immuno-oncology. By employing this innovative approach, Mebias Discovery seeks to reduce the risks commonly associated with conventional drug development methods, thus providing new therapeutic avenues for various health issues.

RiboNova Inc. is a biopharmaceutical company based in Wynnewood, Pennsylvania, focused on developing small molecule drugs aimed at treating serious rare diseases, including certain cancers and mitochondrial diseases. Incorporated in 2011, RiboNova leverages a drug discovery platform that targets defective transfer RNA molecules, which play a critical role in cellular function. The company's innovative approach centers on precision medicines that address ribonucleic acid anomalies, providing healthcare professionals with new treatment options for patients suffering from genetically confirmed mitochondrial conditions and select cancer types. RiboNova operates within the Lankenau Institute for Medical Research near Philadelphia, emphasizing its commitment to advancing therapeutic solutions in the field of rare diseases.

Hsiri Therapeutics, LLC is a development stage pharmaceutical company focused on creating new antibiotics to combat serious infectious diseases caused by drug-resistant bacteria. The company targets two primary groups of pathogens: mycobacterial diseases and gram-negative infections. Notably, it is developing treatments for methicillin-resistant Staphylococcus aureus, drug-resistant Mycobacterium tuberculosis, and infections caused by Mycobacterium avium intracellulare and Pseudomonas aeruginosa, particularly in hospitalized patients. Hsiri's product pipeline includes HT-01, a topical compound for gram-positive infections; HT-02, for serious gram-positive infections; HT-03, an anti-mycobacterial agent; HT-04, for drug-resistant Mycobacterium tuberculosis; and HT-05, which features novel modifications of the standard amino-penicillin framework. The company also explores therapies for Acinetobacter and Klebsiella infections. Founded in 2012 and based in Media, Pennsylvania, Hsiri Therapeutics evolved from antibiotic research initiated by Professor Marvin Miller at the University of Notre Dame.

CarePartners Plus, LLC is a technology-driven healthcare communications and data company based in Horsham, Pennsylvania. Established in 2009, it specializes in providing patient management solutions through its Wellby platform, a cloud-based system that enhances patient engagement and care coordination. The platform captures and analyzes patient-generated information in real time, facilitating better healthcare experiences and outcomes. CarePartners Plus serves a diverse range of clients, including pharmaceutical companies, health insurers, hospitals, medical groups, employers, government agencies, and educators. By focusing on patient-centric approaches, the company aims to transform healthcare delivery and align stakeholder incentives towards improved compliance and satisfaction.

Allevi develops innovative tools for designing and engineering 3D tissues, focusing on bioprinting technology. The company offers desktop 3D bioprinters that allow users to create functional three-dimensional living tissues using various biomaterials and cell lines. Additionally, Allevi provides bioinks made from collagen and hyaluronic acid, which are available for purchase online. Their cloud-based platform, Bioprint Online, enables users to design complex structures, define materials, and monitor the printing process. Allevi's products serve a diverse clientele, including researchers in tissue engineering, regenerative medicine, and cell biology, as well as industrial and pharmaceutical companies for drug testing and development, and educators. Established in 2014 and based in Philadelphia, Pennsylvania, Allevi was formerly known as BioBots, Inc.

Galleon Pharmaceuticals, Inc. is a pharmaceutical company based in Horsham, Pennsylvania, founded in 2003. It specializes in discovering and developing treatments for sleep apnea and related breathing control disorders. The company has a portfolio of therapeutics, including GAL-021, a small molecule administered intravenously to support respiratory drive in surgical and critical care patients, and GLN-21,160, an oral candidate aimed at treating sleep apnea. Additionally, Galleon is developing GAL-044, a small molecule designed to prevent surgical pain. The company's focus extends to addressing conditions such as ventilator weaning, anesthetic-induced respiratory depression, chronic obstructive pulmonary disease (COPD), and obesity-hypoventilation syndrome, with the goal of improving respiratory health for patients.

HealthQX, founded in 2012 and based in King of Prussia, Pennsylvania, specializes in value-based payment analytic software solutions tailored for health plans and providers. The company's primary offering, ClarityQx, is a comprehensive analytics platform designed to facilitate the design, implementation, and ongoing performance monitoring of various payment models, including episodic, bundled, and accountable care arrangements. This platform provides users with drill-down dashboards that enhance provider engagement and streamline contract negotiation processes. By enabling quick access to critical payment analytics, HealthQX aims to improve consumer care and reduce medical costs within the healthcare industry.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing small molecule drugs and therapeutics aimed at treating various chronic diseases. Established in 2004, the company specializes in creating peripherally selective agents for conditions such as diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), obesity, autoimmune and inflammatory disorders, and malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these therapeutic areas.

Merganser Biotech, Inc. is a research and development company focused on creating innovative medicines for the treatment of rare hematological and iron overload diseases, such as hemochromatosis, polycythemia vera, acute severe infections, and beta thalassemia. The company specializes in the development of hepcidin mimetic peptides, which are designed to regulate iron metabolism and address ineffective erythropoiesis. Founded in 2011, Merganser Biotech is headquartered in King of Prussia, Pennsylvania.

Hsiri Therapeutics, LLC is a development stage pharmaceutical company focused on creating new antibiotics to combat serious infectious diseases caused by drug-resistant bacteria. The company targets two primary groups of pathogens: mycobacterial diseases and gram-negative infections. Notably, it is developing treatments for methicillin-resistant Staphylococcus aureus, drug-resistant Mycobacterium tuberculosis, and infections caused by Mycobacterium avium intracellulare and Pseudomonas aeruginosa, particularly in hospitalized patients. Hsiri's product pipeline includes HT-01, a topical compound for gram-positive infections; HT-02, for serious gram-positive infections; HT-03, an anti-mycobacterial agent; HT-04, for drug-resistant Mycobacterium tuberculosis; and HT-05, which features novel modifications of the standard amino-penicillin framework. The company also explores therapies for Acinetobacter and Klebsiella infections. Founded in 2012 and based in Media, Pennsylvania, Hsiri Therapeutics evolved from antibiotic research initiated by Professor Marvin Miller at the University of Notre Dame.

Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on discovering and developing antiviral drugs for chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. The company specializes in creating first-in-class oral therapeutics that target the capsid of these viruses, offering potential treatment options that address significant limitations in current therapies. Novira's innovative capsid inhibitors can be used alone or in conjunction with existing treatments, aiming to overcome challenges such as drug resistance and the need for lifelong therapy, particularly in chronic HBV infection, where existing polymerase inhibitors are rarely curative. Founded in 2006, Novira Therapeutics operates as a subsidiary of Johnson & Johnson, reflecting its strategic importance in addressing global health needs related to antiviral treatment.

Immunome Inc., founded in 2006 and headquartered in Exton, Pennsylvania, is a biotechnology company focused on discovering, developing, and commercializing highly targeted and native human cancer antibodies against universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that target them. Additionally, Immunome employs ScreenMab multiplex functional screening technology to pinpoint monoclonal antibodies with high specificity for tumor neoantigens.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing small molecule drugs and therapeutics aimed at treating various chronic diseases. Established in 2004, the company specializes in creating peripherally selective agents for conditions such as diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), obesity, autoimmune and inflammatory disorders, and malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these therapeutic areas.

HealthQX, founded in 2012 and based in King of Prussia, Pennsylvania, specializes in value-based payment analytic software solutions tailored for health plans and providers. The company's primary offering, ClarityQx, is a comprehensive analytics platform designed to facilitate the design, implementation, and ongoing performance monitoring of various payment models, including episodic, bundled, and accountable care arrangements. This platform provides users with drill-down dashboards that enhance provider engagement and streamline contract negotiation processes. By enabling quick access to critical payment analytics, HealthQX aims to improve consumer care and reduce medical costs within the healthcare industry.

Merganser Biotech, Inc. is a research and development company focused on creating innovative medicines for the treatment of rare hematological and iron overload diseases, such as hemochromatosis, polycythemia vera, acute severe infections, and beta thalassemia. The company specializes in the development of hepcidin mimetic peptides, which are designed to regulate iron metabolism and address ineffective erythropoiesis. Founded in 2011, Merganser Biotech is headquartered in King of Prussia, Pennsylvania.

Venatorx Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections and challenging viral infections. Founded in 2010 and based in Malvern, Pennsylvania, the company specializes in developing antibacterial drugs to combat resistant infections commonly encountered in hospital and community settings, such as those caused by MRSA, Pseudomonas spp., and Salmonella spp. Venatorx employs innovative chemical approaches to create treatments that exhibit selective and potent activity against various resistant bacterial strains, thereby providing healthcare professionals with broader treatment options to address significant unmet medical needs.

Immunome Inc., founded in 2006 and headquartered in Exton, Pennsylvania, is a biotechnology company focused on discovering, developing, and commercializing highly targeted and native human cancer antibodies against universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that target them. Additionally, Immunome employs ScreenMab multiplex functional screening technology to pinpoint monoclonal antibodies with high specificity for tumor neoantigens.

Annovis Bio, Inc. is a clinical-stage pharmaceutical company based in Berwyn, Pennsylvania, specializing in the development of treatments for neurodegenerative disorders, particularly Alzheimer's disease and Parkinson's disease. The company is advancing several compounds in clinical trials, with its lead candidate, ANVS401, currently in Phase 2a trials aimed at treating Alzheimer’s disease, Parkinson’s disease, and other chronic neurodegenerative conditions. Additionally, Annovis is developing ANVS405, which focuses on providing neuroprotection following traumatic brain injuries and strokes, and ANVS301, which is in Phase I trials designed to enhance cognitive function in later stages of Alzheimer’s disease and dementia. Founded in 2008, Annovis Bio is dedicated to creating innovative therapies to address the challenges posed by these debilitating diseases.

Merganser Biotech, Inc. is a research and development company focused on creating innovative medicines for the treatment of rare hematological and iron overload diseases, such as hemochromatosis, polycythemia vera, acute severe infections, and beta thalassemia. The company specializes in the development of hepcidin mimetic peptides, which are designed to regulate iron metabolism and address ineffective erythropoiesis. Founded in 2011, Merganser Biotech is headquartered in King of Prussia, Pennsylvania.

Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on discovering and developing antiviral drugs for chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. The company specializes in creating first-in-class oral therapeutics that target the capsid of these viruses, offering potential treatment options that address significant limitations in current therapies. Novira's innovative capsid inhibitors can be used alone or in conjunction with existing treatments, aiming to overcome challenges such as drug resistance and the need for lifelong therapy, particularly in chronic HBV infection, where existing polymerase inhibitors are rarely curative. Founded in 2006, Novira Therapeutics operates as a subsidiary of Johnson & Johnson, reflecting its strategic importance in addressing global health needs related to antiviral treatment.

Immunome Inc., founded in 2006 and headquartered in Exton, Pennsylvania, is a biotechnology company focused on discovering, developing, and commercializing highly targeted and native human cancer antibodies against universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that target them. Additionally, Immunome employs ScreenMab multiplex functional screening technology to pinpoint monoclonal antibodies with high specificity for tumor neoantigens.

Life Mist Technologies, Inc., based in Paoli, Pennsylvania, specializes in developing and commercializing an innovative atomization technology that generates a high volume of micron-sized droplets using low-pressure gas and liquid. This technology is designed for a diverse array of industrial applications, including aircraft fire suppression, chemical processing, emission control, turbine inlet cooling, and decontamination. Additionally, it serves sectors such as artificial snow production and cooling systems. By leveraging its unique atomization capabilities, Life Mist Technologies aims to enhance existing processes and provide effective solutions to various industrial challenges. The company has been operational since its incorporation in 2004.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing small molecule drugs and therapeutics aimed at treating various chronic diseases. Established in 2004, the company specializes in creating peripherally selective agents for conditions such as diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), obesity, autoimmune and inflammatory disorders, and malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these therapeutic areas.

Merganser Biotech, Inc. is a research and development company focused on creating innovative medicines for the treatment of rare hematological and iron overload diseases, such as hemochromatosis, polycythemia vera, acute severe infections, and beta thalassemia. The company specializes in the development of hepcidin mimetic peptides, which are designed to regulate iron metabolism and address ineffective erythropoiesis. Founded in 2011, Merganser Biotech is headquartered in King of Prussia, Pennsylvania.

Innovative Supply Solutions LLC is a specialty contract service organization based in Southampton, Pennsylvania, focused on clinical drug supply chain management. The company offers a comprehensive range of services, including planning and forecasting for active pharmaceutical ingredients and formulated products, project and budget management, inventory oversight, and supply chain coordination. Additionally, it provides support in manufacturing, packaging design, labeling, distribution, and consultancy. Innovative Supply Solutions has developed proprietary software that enhances the efficiency and effectiveness of supply chain management by facilitating coordination and reducing risks associated with clinical trials. This technology has been in use since 2010, delivering accurate forecast results with variances of less than 10%. The company aims to support healthcare providers by lowering costs and improving the overall management of clinical drug supplies.

Innovative Supply Solutions LLC is a specialty contract service organization based in Southampton, Pennsylvania, focused on clinical drug supply chain management. The company offers a comprehensive range of services, including planning and forecasting for active pharmaceutical ingredients and formulated products, project and budget management, inventory oversight, and supply chain coordination. Additionally, it provides support in manufacturing, packaging design, labeling, distribution, and consultancy. Innovative Supply Solutions has developed proprietary software that enhances the efficiency and effectiveness of supply chain management by facilitating coordination and reducing risks associated with clinical trials. This technology has been in use since 2010, delivering accurate forecast results with variances of less than 10%. The company aims to support healthcare providers by lowering costs and improving the overall management of clinical drug supplies.

Melior Discovery, Inc. is a biotechnology company that specializes in identifying novel therapeutic applications for existing drugs through its in vivo pharmacology platform. Founded in 2005 and based in Exton, Pennsylvania, Melior utilizes its theraTRACE indications discovery platform to systematically evaluate compounds across multiple validated in vivo models. This approach allows the company to explore potential therapeutic uses in various areas, including neurodegenerative diseases, psychiatry, inflammation, pain management, metabolic disorders, gastrointestinal and urology, cardiovascular diseases, and dermatology. By offering rapid and cost-effective screening solutions, Melior Discovery serves clients in the pharmaceutical and biopharmaceutical industries, assisting them in uncovering new indications for pre-clinical and development-stage drug candidates.

Imiplex LLC is a biotechnology company based in Bristol, Pennsylvania, that specializes in developing protein-based nanotechnology for applications in biosensors, biomaterials, and targeted therapeutic and diagnostic agents. Founded in 2003, Imiplex has created a platform known as TriPol, which consists of modular components engineered from proteins. This technology leverages the unique properties of proteins, such as their ability to self-assemble with atomic precision and their structural diversity, to construct various nanostructures. These engineered protein nanostructures support early diagnosis and treatment of diseases, including cancer, diabetes, and neurodegenerative disorders like Alzheimer's disease.

CarePartners Plus, LLC is a technology-driven healthcare communications and data company based in Horsham, Pennsylvania. Established in 2009, it specializes in providing patient management solutions through its Wellby platform, a cloud-based system that enhances patient engagement and care coordination. The platform captures and analyzes patient-generated information in real time, facilitating better healthcare experiences and outcomes. CarePartners Plus serves a diverse range of clients, including pharmaceutical companies, health insurers, hospitals, medical groups, employers, government agencies, and educators. By focusing on patient-centric approaches, the company aims to transform healthcare delivery and align stakeholder incentives towards improved compliance and satisfaction.

Galleon Pharmaceuticals, Inc. is a pharmaceutical company based in Horsham, Pennsylvania, founded in 2003. It specializes in discovering and developing treatments for sleep apnea and related breathing control disorders. The company has a portfolio of therapeutics, including GAL-021, a small molecule administered intravenously to support respiratory drive in surgical and critical care patients, and GLN-21,160, an oral candidate aimed at treating sleep apnea. Additionally, Galleon is developing GAL-044, a small molecule designed to prevent surgical pain. The company's focus extends to addressing conditions such as ventilator weaning, anesthetic-induced respiratory depression, chronic obstructive pulmonary disease (COPD), and obesity-hypoventilation syndrome, with the goal of improving respiratory health for patients.

Immunome Inc., founded in 2006 and headquartered in Exton, Pennsylvania, is a biotechnology company focused on discovering, developing, and commercializing highly targeted and native human cancer antibodies against universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that target them. Additionally, Immunome employs ScreenMab multiplex functional screening technology to pinpoint monoclonal antibodies with high specificity for tumor neoantigens.

Melior Discovery, Inc. is a biotechnology company that specializes in identifying novel therapeutic applications for existing drugs through its in vivo pharmacology platform. Founded in 2005 and based in Exton, Pennsylvania, Melior utilizes its theraTRACE indications discovery platform to systematically evaluate compounds across multiple validated in vivo models. This approach allows the company to explore potential therapeutic uses in various areas, including neurodegenerative diseases, psychiatry, inflammation, pain management, metabolic disorders, gastrointestinal and urology, cardiovascular diseases, and dermatology. By offering rapid and cost-effective screening solutions, Melior Discovery serves clients in the pharmaceutical and biopharmaceutical industries, assisting them in uncovering new indications for pre-clinical and development-stage drug candidates.

Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on discovering and developing antiviral drugs for chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. The company specializes in creating first-in-class oral therapeutics that target the capsid of these viruses, offering potential treatment options that address significant limitations in current therapies. Novira's innovative capsid inhibitors can be used alone or in conjunction with existing treatments, aiming to overcome challenges such as drug resistance and the need for lifelong therapy, particularly in chronic HBV infection, where existing polymerase inhibitors are rarely curative. Founded in 2006, Novira Therapeutics operates as a subsidiary of Johnson & Johnson, reflecting its strategic importance in addressing global health needs related to antiviral treatment.

Immunome Inc., founded in 2006 and headquartered in Exton, Pennsylvania, is a biotechnology company focused on discovering, developing, and commercializing highly targeted and native human cancer antibodies against universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that target them. Additionally, Immunome employs ScreenMab multiplex functional screening technology to pinpoint monoclonal antibodies with high specificity for tumor neoantigens.

Immunome Inc., founded in 2006 and headquartered in Exton, Pennsylvania, is a biotechnology company focused on discovering, developing, and commercializing highly targeted and native human cancer antibodies against universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that target them. Additionally, Immunome employs ScreenMab multiplex functional screening technology to pinpoint monoclonal antibodies with high specificity for tumor neoantigens.

Leversense, LLC intends to develop a medical device for detecting AIDS, food toxin, and mycoplasma bacteria. The company was incorporated in 2009 and is based in Newtown Square, Pennsylvania.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing small molecule drugs and therapeutics aimed at treating various chronic diseases. Established in 2004, the company specializes in creating peripherally selective agents for conditions such as diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), obesity, autoimmune and inflammatory disorders, and malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these therapeutic areas.

Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on discovering and developing antiviral drugs for chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. The company specializes in creating first-in-class oral therapeutics that target the capsid of these viruses, offering potential treatment options that address significant limitations in current therapies. Novira's innovative capsid inhibitors can be used alone or in conjunction with existing treatments, aiming to overcome challenges such as drug resistance and the need for lifelong therapy, particularly in chronic HBV infection, where existing polymerase inhibitors are rarely curative. Founded in 2006, Novira Therapeutics operates as a subsidiary of Johnson & Johnson, reflecting its strategic importance in addressing global health needs related to antiviral treatment.

Immunome Inc., founded in 2006 and headquartered in Exton, Pennsylvania, is a biotechnology company focused on discovering, developing, and commercializing highly targeted and native human cancer antibodies against universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that target them. Additionally, Immunome employs ScreenMab multiplex functional screening technology to pinpoint monoclonal antibodies with high specificity for tumor neoantigens.

Formae, Inc. is a company specializing in arthroscopic joint resurfacing and replacement technologies, founded in 2006 and based in Paoli, Pennsylvania. It develops innovative products, including a biocompatible implant known as ArthroPad, which provides a minimally invasive surgical solution for replacing damaged cartilage in arthritic joints. The company's focus is on addressing conditions such as arthritis and joint destruction, utilizing proprietary synthetic cartilage to enhance patient outcomes in joint health.

Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on discovering and developing antiviral drugs for chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. The company specializes in creating first-in-class oral therapeutics that target the capsid of these viruses, offering potential treatment options that address significant limitations in current therapies. Novira's innovative capsid inhibitors can be used alone or in conjunction with existing treatments, aiming to overcome challenges such as drug resistance and the need for lifelong therapy, particularly in chronic HBV infection, where existing polymerase inhibitors are rarely curative. Founded in 2006, Novira Therapeutics operates as a subsidiary of Johnson & Johnson, reflecting its strategic importance in addressing global health needs related to antiviral treatment.

Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on discovering and developing antiviral drugs for chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. The company specializes in creating first-in-class oral therapeutics that target the capsid of these viruses, offering potential treatment options that address significant limitations in current therapies. Novira's innovative capsid inhibitors can be used alone or in conjunction with existing treatments, aiming to overcome challenges such as drug resistance and the need for lifelong therapy, particularly in chronic HBV infection, where existing polymerase inhibitors are rarely curative. Founded in 2006, Novira Therapeutics operates as a subsidiary of Johnson & Johnson, reflecting its strategic importance in addressing global health needs related to antiviral treatment.

Annovis Bio, Inc. is a clinical-stage pharmaceutical company based in Berwyn, Pennsylvania, specializing in the development of treatments for neurodegenerative disorders, particularly Alzheimer's disease and Parkinson's disease. The company is advancing several compounds in clinical trials, with its lead candidate, ANVS401, currently in Phase 2a trials aimed at treating Alzheimer’s disease, Parkinson’s disease, and other chronic neurodegenerative conditions. Additionally, Annovis is developing ANVS405, which focuses on providing neuroprotection following traumatic brain injuries and strokes, and ANVS301, which is in Phase I trials designed to enhance cognitive function in later stages of Alzheimer’s disease and dementia. Founded in 2008, Annovis Bio is dedicated to creating innovative therapies to address the challenges posed by these debilitating diseases.

Melior Discovery, Inc. is a biotechnology company that specializes in identifying novel therapeutic applications for existing drugs through its in vivo pharmacology platform. Founded in 2005 and based in Exton, Pennsylvania, Melior utilizes its theraTRACE indications discovery platform to systematically evaluate compounds across multiple validated in vivo models. This approach allows the company to explore potential therapeutic uses in various areas, including neurodegenerative diseases, psychiatry, inflammation, pain management, metabolic disorders, gastrointestinal and urology, cardiovascular diseases, and dermatology. By offering rapid and cost-effective screening solutions, Melior Discovery serves clients in the pharmaceutical and biopharmaceutical industries, assisting them in uncovering new indications for pre-clinical and development-stage drug candidates.

Innovative Supply Solutions LLC is a specialty contract service organization based in Southampton, Pennsylvania, focused on clinical drug supply chain management. The company offers a comprehensive range of services, including planning and forecasting for active pharmaceutical ingredients and formulated products, project and budget management, inventory oversight, and supply chain coordination. Additionally, it provides support in manufacturing, packaging design, labeling, distribution, and consultancy. Innovative Supply Solutions has developed proprietary software that enhances the efficiency and effectiveness of supply chain management by facilitating coordination and reducing risks associated with clinical trials. This technology has been in use since 2010, delivering accurate forecast results with variances of less than 10%. The company aims to support healthcare providers by lowering costs and improving the overall management of clinical drug supplies.

Temple University, located in Philadelphia, Pennsylvania, is one of the largest four-year institutions in the United States, renowned for its comprehensive academic offerings and strong emphasis on professional education. The university provides over 300 academic programs, leading to degrees at the bachelor’s, master’s, and doctoral levels, with a notable reputation for producing skilled professionals in fields such as medicine, law, and engineering. In addition to its academic rigor, Temple is committed to research across various disciplines, including aging and biostatistics, contributing to a vibrant educational environment. The university fosters a dynamic student life with over 200 organizations and various cultural activities. Temple University manages an endowment fund, which consists of designated gifts and investments aimed at providing a sustainable income source to support its ongoing operations. The endowment is overseen by the board of trustees, with guidance from the budget and finance committee and investment committee, ensuring the preservation and growth of its financial resources for future generations.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing small molecule drugs and therapeutics aimed at treating various chronic diseases. Established in 2004, the company specializes in creating peripherally selective agents for conditions such as diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), obesity, autoimmune and inflammatory disorders, and malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these therapeutic areas.

Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on discovering and developing antiviral drugs for chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. The company specializes in creating first-in-class oral therapeutics that target the capsid of these viruses, offering potential treatment options that address significant limitations in current therapies. Novira's innovative capsid inhibitors can be used alone or in conjunction with existing treatments, aiming to overcome challenges such as drug resistance and the need for lifelong therapy, particularly in chronic HBV infection, where existing polymerase inhibitors are rarely curative. Founded in 2006, Novira Therapeutics operates as a subsidiary of Johnson & Johnson, reflecting its strategic importance in addressing global health needs related to antiviral treatment.

Immunome Inc., founded in 2006 and headquartered in Exton, Pennsylvania, is a biotechnology company focused on discovering, developing, and commercializing highly targeted and native human cancer antibodies against universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that target them. Additionally, Immunome employs ScreenMab multiplex functional screening technology to pinpoint monoclonal antibodies with high specificity for tumor neoantigens.

Avid Radiopharmaceuticals is a biopharmaceutical company based in Philadelphia, PA, focused on developing molecular imaging agents designed to improve the medical management of chronic diseases. The company aims to create innovative imaging compounds that can detect and monitor the early stages of pathological changes, facilitating earlier diagnoses and enhancing the management of treatment options. One of their key products, Amyvid, serves as an imaging tool for positron emission tomography, specifically targeting the detection of beta-amyloid plaques in the brain, which is crucial for understanding conditions like Alzheimer's disease. Avid's mission underscores their commitment to transforming disease management through advanced imaging technologies.

Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on discovering and developing antiviral drugs for chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. The company specializes in creating first-in-class oral therapeutics that target the capsid of these viruses, offering potential treatment options that address significant limitations in current therapies. Novira's innovative capsid inhibitors can be used alone or in conjunction with existing treatments, aiming to overcome challenges such as drug resistance and the need for lifelong therapy, particularly in chronic HBV infection, where existing polymerase inhibitors are rarely curative. Founded in 2006, Novira Therapeutics operates as a subsidiary of Johnson & Johnson, reflecting its strategic importance in addressing global health needs related to antiviral treatment.

Formae, Inc. is a company specializing in arthroscopic joint resurfacing and replacement technologies, founded in 2006 and based in Paoli, Pennsylvania. It develops innovative products, including a biocompatible implant known as ArthroPad, which provides a minimally invasive surgical solution for replacing damaged cartilage in arthritic joints. The company's focus is on addressing conditions such as arthritis and joint destruction, utilizing proprietary synthetic cartilage to enhance patient outcomes in joint health.

Melior Discovery, Inc. is a biotechnology company that specializes in identifying novel therapeutic applications for existing drugs through its in vivo pharmacology platform. Founded in 2005 and based in Exton, Pennsylvania, Melior utilizes its theraTRACE indications discovery platform to systematically evaluate compounds across multiple validated in vivo models. This approach allows the company to explore potential therapeutic uses in various areas, including neurodegenerative diseases, psychiatry, inflammation, pain management, metabolic disorders, gastrointestinal and urology, cardiovascular diseases, and dermatology. By offering rapid and cost-effective screening solutions, Melior Discovery serves clients in the pharmaceutical and biopharmaceutical industries, assisting them in uncovering new indications for pre-clinical and development-stage drug candidates.

Avid Radiopharmaceuticals is a biopharmaceutical company based in Philadelphia, PA, focused on developing molecular imaging agents designed to improve the medical management of chronic diseases. The company aims to create innovative imaging compounds that can detect and monitor the early stages of pathological changes, facilitating earlier diagnoses and enhancing the management of treatment options. One of their key products, Amyvid, serves as an imaging tool for positron emission tomography, specifically targeting the detection of beta-amyloid plaques in the brain, which is crucial for understanding conditions like Alzheimer's disease. Avid's mission underscores their commitment to transforming disease management through advanced imaging technologies.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing small molecule drugs and therapeutics aimed at treating various chronic diseases. Established in 2004, the company specializes in creating peripherally selective agents for conditions such as diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), obesity, autoimmune and inflammatory disorders, and malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these therapeutic areas.

StageMark develops and markets inflammatory diseases identification and monitoring solutions. The company's product, CB-CAPs, enables user to analyze complement products bound to various blood cell types such as erythrocytes, platelets, reticulocytes, and lymphocytes. StageMark, Inc. was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania.

Avid Radiopharmaceuticals is a biopharmaceutical company based in Philadelphia, PA, focused on developing molecular imaging agents designed to improve the medical management of chronic diseases. The company aims to create innovative imaging compounds that can detect and monitor the early stages of pathological changes, facilitating earlier diagnoses and enhancing the management of treatment options. One of their key products, Amyvid, serves as an imaging tool for positron emission tomography, specifically targeting the detection of beta-amyloid plaques in the brain, which is crucial for understanding conditions like Alzheimer's disease. Avid's mission underscores their commitment to transforming disease management through advanced imaging technologies.

Avid Radiopharmaceuticals is a biopharmaceutical company based in Philadelphia, PA, focused on developing molecular imaging agents designed to improve the medical management of chronic diseases. The company aims to create innovative imaging compounds that can detect and monitor the early stages of pathological changes, facilitating earlier diagnoses and enhancing the management of treatment options. One of their key products, Amyvid, serves as an imaging tool for positron emission tomography, specifically targeting the detection of beta-amyloid plaques in the brain, which is crucial for understanding conditions like Alzheimer's disease. Avid's mission underscores their commitment to transforming disease management through advanced imaging technologies.

Protez Pharmaceuticals is a medical research company that discovers, develops, and commercializes antibiotics for difficult-to-treat hospital-based infections. The company focuses on differentiated intravenous and oral small molecule antibiotics to address bacterial resistant, and chronic or recurrent infections. Protez Pharmaceuticals was founded by Christopher M. Cashman in 2003 and is headquartered in Malvern, Pennsylvania.

NexusPharma, established in 2004 and headquartered in Philadelphia, specializes in drug discovery for cancer treatments. The company creates and tests patient-derived cancer xenograft models, offering these to pharmaceutical and biotechnology firms for validating investigational drugs and identifying biomarkers. NexusPharma's portfolio includes small-molecule protein-protein interaction inhibitors, developed using a multidisciplinary approach that combines medicinal chemistry, biology, and informatics. The company operates as a subsidiary of Genesis Biotechnology Group, LLC.

EyeIC, Inc. is a medical technology company focused on developing and commercializing imaging technologies for eye care applications. Based in Wayne, Pennsylvania, EyeIC serves eye care professionals and clinics by offering the MatchedFlicker device, which monitors the onset and progression of glaucoma through change detection in time series retinal photographs. The technology aligns and registers images taken at different times, creating a superimposed view that aids in accurate diagnosis. Additionally, EyeIC's software includes an easy-to-use application that streamlines image processing, interpretation, and reporting, facilitating the detection of various retinal conditions such as diabetic retinopathy and retinopathy of prematurity. Established in 2004, EyeIC aims to simplify workflows for clinicians and enhance patient care in the field of ophthalmology.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing small molecule drugs and therapeutics aimed at treating various chronic diseases. Established in 2004, the company specializes in creating peripherally selective agents for conditions such as diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), obesity, autoimmune and inflammatory disorders, and malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these therapeutic areas.

Avid Radiopharmaceuticals is a biopharmaceutical company based in Philadelphia, PA, focused on developing molecular imaging agents designed to improve the medical management of chronic diseases. The company aims to create innovative imaging compounds that can detect and monitor the early stages of pathological changes, facilitating earlier diagnoses and enhancing the management of treatment options. One of their key products, Amyvid, serves as an imaging tool for positron emission tomography, specifically targeting the detection of beta-amyloid plaques in the brain, which is crucial for understanding conditions like Alzheimer's disease. Avid's mission underscores their commitment to transforming disease management through advanced imaging technologies.

Galleon Pharmaceuticals, Inc. is a pharmaceutical company based in Horsham, Pennsylvania, founded in 2003. It specializes in discovering and developing treatments for sleep apnea and related breathing control disorders. The company has a portfolio of therapeutics, including GAL-021, a small molecule administered intravenously to support respiratory drive in surgical and critical care patients, and GLN-21,160, an oral candidate aimed at treating sleep apnea. Additionally, Galleon is developing GAL-044, a small molecule designed to prevent surgical pain. The company's focus extends to addressing conditions such as ventilator weaning, anesthetic-induced respiratory depression, chronic obstructive pulmonary disease (COPD), and obesity-hypoventilation syndrome, with the goal of improving respiratory health for patients.

Melior Discovery, Inc. is a biotechnology company that specializes in identifying novel therapeutic applications for existing drugs through its in vivo pharmacology platform. Founded in 2005 and based in Exton, Pennsylvania, Melior utilizes its theraTRACE indications discovery platform to systematically evaluate compounds across multiple validated in vivo models. This approach allows the company to explore potential therapeutic uses in various areas, including neurodegenerative diseases, psychiatry, inflammation, pain management, metabolic disorders, gastrointestinal and urology, cardiovascular diseases, and dermatology. By offering rapid and cost-effective screening solutions, Melior Discovery serves clients in the pharmaceutical and biopharmaceutical industries, assisting them in uncovering new indications for pre-clinical and development-stage drug candidates.

LumenVu, Inc., a privately held, development stage company based in Philadelphia.

Acuity Pharmaceuticals is a pharmaceutical company based in Philadelphia, Pennsylvania, established in 2007. It specializes in the treatment and prevention of ophthalmic diseases, particularly focusing on age-related macular degeneration (AMD) and diabetic retinopathy (DR). The company is developing small interfering RNA compounds aimed at addressing vision loss associated with these conditions. One of its key products, Cand5, is a clinical compound designed to inhibit vascular endothelial growth factor, thereby targeting adult vision loss. In June 2011, Acuity Pharmaceuticals was acquired by OPKO Health, enhancing its capabilities in the ophthalmic market.

Acuity Pharmaceuticals is a pharmaceutical company based in Philadelphia, Pennsylvania, established in 2007. It specializes in the treatment and prevention of ophthalmic diseases, particularly focusing on age-related macular degeneration (AMD) and diabetic retinopathy (DR). The company is developing small interfering RNA compounds aimed at addressing vision loss associated with these conditions. One of its key products, Cand5, is a clinical compound designed to inhibit vascular endothelial growth factor, thereby targeting adult vision loss. In June 2011, Acuity Pharmaceuticals was acquired by OPKO Health, enhancing its capabilities in the ophthalmic market.

Protez Pharmaceuticals is a medical research company that discovers, develops, and commercializes antibiotics for difficult-to-treat hospital-based infections. The company focuses on differentiated intravenous and oral small molecule antibiotics to address bacterial resistant, and chronic or recurrent infections. Protez Pharmaceuticals was founded by Christopher M. Cashman in 2003 and is headquartered in Malvern, Pennsylvania.